


In the Claims:

Please cancel claims 27, 28, 30 and 31.

1. (Previously Presented) A compound of formula (I):



wherein:

R¹ is alkyl;

w is 0 or 1;

R¹¹ is H or C<sub>1-3</sub>alkyl;

Ring A is selected from the group consisting of cycloalkyl, cycloalkenyl, aryl, 5-13 membered heterocycle and 5-13 membered heteroaryl;

Ring B is selected from the group consisting of cycloalkyl, cycloalkenyl, aryl, 5-13 membered heterocycle and 5-13 membered heteroaryl;

a, b, c, f, g, and h are the same or different and are each independently 0 or 1;

d and j are the same or different and are independently 1 or 2;

each R² is the same or different and is independently selected from the group consisting of alkylene, alkenylene and alkynylene;

Y¹ and Y² are the same or different and are each independently selected from the group consisting of -O-, -S(O)<sub>q</sub>- and -N(R⁵)-;

q is 0, 1 or 2;

each R³ and R⁴ are the same or different and are each independently selected from the group consisting of H, halo, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, Ph, Het, -COR⁵, -CSR⁵, -CO<sub>2</sub>R⁵, -COPh, -CO<sub>2</sub>Ph, -C(O)Het, -C(O)NR⁵R⁶, -C(S)NR⁵R⁶, -C(=NR⁵)R⁶, -C(=NR⁵)NR⁵R⁶, -CR⁵=N-OR⁶, -OR⁵, -OCOR⁵, -S(O)<sub>p</sub>R⁵, -S(O)<sub>2</sub>OH, -S(O)<sub>p</sub>NR⁵R⁶, -NR⁵R⁶, -NR⁵COR⁶, -NR⁵CO<sub>2</sub>R⁶, -NR⁵SO<sub>2</sub>R⁶, -NO<sub>2</sub>, -CN, -SCN and -N<sub>3</sub>;

each p is the same or different and is 0, 1 or 2;

m and n are the same or different and are each independently 0, 1, 2, 3, 4 or 5;

each R<sup>5</sup> and each R<sup>6</sup> are the same or different and are each independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, cycloalkyl and cycloalkenyl;

Ph is phenyl optionally substituted by one or more substituents selected from the group consisting of halo, alkyl, -CO<sub>2</sub>R<sup>5</sup>, -OR<sup>5</sup>, -SO<sub>2</sub>R<sup>5</sup>, -SO<sub>2</sub>NR<sup>5</sup>R<sup>6</sup>, -NR<sup>5</sup>R<sup>6</sup>, -R<sup>2</sup>-(NR<sup>5</sup>R<sup>6</sup>)CO<sub>2</sub>R<sup>5</sup>, Het, -R<sup>2</sup>-Het, -CN and -N<sub>3</sub>; and

Het is a monocyclic 5-6 membered heterocycle or heteroaryl group containing 1, 2 or 3 heteroatoms selected from the group consisting of N, O and S optionally substituted by one or more substituents selected from the group consisting of halo, alkyl, -CO<sub>2</sub>R<sup>5</sup>, -C(O)NR<sup>5</sup>R<sup>6</sup>, -OR<sup>5</sup>, -SO<sub>2</sub>R<sup>5</sup>, -SO<sub>2</sub>NR<sup>5</sup>R<sup>6</sup>, -NR<sup>5</sup>R<sup>6</sup>, oxo, -CN and -N<sub>3</sub>;

or a pharmaceutically acceptable salt thereof.

2. (Original) The compound according to claim 1, wherein R<sup>1</sup> is methyl.

3. (Previously Presented) The compound according to claim 1, wherein Ring A is selected from the group consisting of aryl and 5-13 membered heteroaryl.

4. (Previously Presented) The compound according to claim 1, wherein Ring A is phenyl.

5. (Previously Presented) The compound according to claim 1, wherein Ring B is selected from the group consisting of phenyl, pyridine and pyrimidine.

6. (Previously Presented) The compound according to claim 1, wherein Ring B is phenyl.

7. (Previously Presented) The compound according to claim 1, wherein each R<sup>2</sup> is the same or different and is independently selected from the group consisting of alkylene and alkenylene.

8. (Previously Presented) The compound according to claim 1, wherein b is 0.

9. (Previously Presented) The compound according to claim 1, wherein b is 1 and Y<sup>1</sup> is selected from the group consisting of -O- and -N(R<sup>5</sup>)-.

10. (Previously Presented) The compound according to claim 1, wherein g is 0.
11. (Previously Presented) The compound according to claim 1, wherein g is 1 and Y<sup>2</sup> is -O-.
12. (Previously Presented) The compound according to claim 1, wherein d is 1.
13. (Previously Presented) The compound according to claim 1, wherein j is 1.
14. (Previously Presented) The compound according to claim 1, wherein each R<sup>3</sup> is the same or different and is independently selected from the group consisting of H, halo, alkyl, alkenyl, cycloalkyl, Ph, Het, -COR<sup>5</sup>, -CO<sub>2</sub>R<sup>5</sup>, -COPh, -C(O)NR<sup>5</sup>R<sup>6</sup>, -OR<sup>5</sup>, -S(O)<sub>p</sub>R<sup>5</sup>, -S(O)<sub>p</sub>NR<sup>5</sup>R<sup>6</sup>, -NR<sup>5</sup>R<sup>6</sup>, -NO<sub>2</sub>, -CN and -N<sub>3</sub>.
15. (Previously Presented) The compound according to claim 1, wherein d is 1 and R<sup>3</sup> is selected from the group consisting of H, halo, alkyl, Ph, -COR<sup>5</sup>, -CO<sub>2</sub>R<sup>5</sup>, -COPh, -C(O)NR<sup>5</sup>R<sup>6</sup>, -OR<sup>5</sup>, -NR<sup>5</sup>R<sup>6</sup>, -NO<sub>2</sub> and -CN.
16. (Previously Presented) The compound according to claim 1, wherein each R<sup>4</sup> is the same or different and is independently selected from the group consisting of H, halo, alkyl, alkenyl, cycloalkyl, Ph, Het, -COR<sup>5</sup>, -CO<sub>2</sub>R<sup>5</sup>, -C(O)NR<sup>5</sup>R<sup>6</sup>, -OR<sup>5</sup>, -S(O)<sub>p</sub>R<sup>5</sup>, -S(O)<sub>2</sub>OH, -S(O)<sub>p</sub>NR<sup>5</sup>R<sup>6</sup>, -NR<sup>5</sup>R<sup>6</sup>, -NR<sup>5</sup>COR<sup>6</sup>, -NO<sub>2</sub> and -CN.
17. (Previously Presented) The compound according to claim 1, wherein j is 1 and R<sup>4</sup> is selected from the group consisting of H, halo, alkyl, -COR<sup>5</sup>, -CO<sub>2</sub>R<sup>5</sup>, -C(O)NR<sup>5</sup>R<sup>6</sup>, -OR<sup>5</sup>, -S(O)<sub>p</sub>R<sup>5</sup>, -S(O)<sub>2</sub>OH, -S(O)<sub>p</sub>NR<sup>5</sup>R<sup>6</sup> and -NO<sub>2</sub>.
18. (Previously Presented) The compound according to claim 1, wherein m is 0, 1, 2 or 3.

19. (Previously Presented) The compound according to claim 1, wherein n is 1, 2, or 3.

20. (Previously Presented) The compound according to claim 1, wherein each R<sup>5</sup> and each R<sup>6</sup> are the same or different and are each independently selected from the group consisting of H, alkyl, alkenyl and cycloalkyl.

21. (Previously Presented) The compound according to claim 1, wherein each R<sup>5</sup> and each R<sup>6</sup> are the same or different and are each independently selected from the group consisting of H and alkyl.

22. (Previously Presented) A compound selected from the group consisting of:

5-Methyl-7-phenyl-N-(3,4,5-trimethoxyphenyl)imidazo[5,1-f][1,2,4]triazin-2-amine;

5-Methyl-7-(2-nitrophenyl)-N-(3,4,5-trimethoxyphenyl)imidazo[5,1-f][1,2,4]triazin-2-amine;

7-(2-Bromophenyl)-5-methyl-N-(3,4,5-trimethoxyphenyl)imidazo[5,1-f][1,2,4]triazin-2-amine;

7-(4-Fluorophenyl)-5-methyl-N-(3,4,5-trimethoxyphenyl)imidazo[5,1-f][1,2,4]triazin-2-amine;

5-Methyl-7-[3-(trifluoromethyl)phenyl]-N-(3,4,5-trimethoxyphenyl)imidazo[5,1-f][1,2,4]triazin-2-amine;

2,2-Dimethyl-N-(2-(5-methyl-2-[(3,4,5-trimethoxyphenyl)amino]imidazo[5,1-f][1,2,4]triazin-7-yl)phenyl)propanamide;

2,2,2-Trifluoro-N-(2-(5-methyl-2-[(3,4,5-trimethoxyphenyl)amino]imidazo[5,1-f][1,2,4]triazin-7-yl)phenyl)acetamide;

3-{5-Methyl-2-[(3,4,5-trimethoxyphenyl)amino]imidazo[5,1-f][1,2,4]triazin-7-yl}benzonitrile;

7-(3-Bromophenyl)-5-methyl-N-(3,4,5-trimethoxyphenyl)imidazo[5,1-f][1,2,4]triazin-2-amine;

7-(3-Bromothien-2-yl)-5-methyl-N-(3,4,5-trimethoxyphenyl)imidazo[5,1-f][1,2,4]triazin-2-amine;

7-(5-Bromopyridin-3-yl)-5-methyl-N-(3,4,5-trimethoxyphenyl)imidazo[5,1-f][1,2,4]triazin-2-amine;

Methyl 3-{5-methyl-2-[(3,4,5-trimethoxyphenyl)amino]imidazo[5,1-*f*][1,2,4]triazin-7-yl}benzoate;

7-(5-Bromothien-2-yl)-5-methyl-N-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;

7-(3-Bromophenyl)-N-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-methylimidazo[5,1-*f*][1,2,4]triazin-2-amine;

7-(3-Bromophenyl)-N-(3-chloro-4-morpholin-4-ylphenyl)-5-methylimidazo[5,1-*f*][1,2,4]triazin-2-amine;

3-{5-Methyl-2-[(3,4,5-trimethoxyphenyl)amino]imidazo[5,1-*f*][1,2,4]triazin-7-yl}benzamide;

(2*E*)-3-(3-{5-Methyl-2-[(3,4,5-trimethoxyphenyl)amino]imidazo[5,1-*f*][1,2,4]triazin-7-yl}phenyl)prop-2-enamide;

5-Methyl-N-(4-nitrophenyl)-7-phenylimidazo[5,1-*f*][1,2,4]triazin-2-amine;

2-{3-[(5-Methyl-7-phenylimidazo[5,1-*f*][1,2,4]triazin-2-yl)amino]phenyl}ethanol;

4-[(5-Methyl-7-phenylimidazo[5,1-*f*][1,2,4]triazin-2-yl)amino]benzene-sulfonamide;

7-(2-Methoxyphenyl)-5-methyl-N-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;

2-{5-Methyl-2-[(3,4,5-trimethoxyphenyl)amino]imidazo[5,1-*f*][1,2,4]triazin-7-yl}phenol;

2-{5-Methyl-2-[(3,4,5-trimethoxyphenyl)amino]imidazo[5,1-*f*][1,2,4]triazin-7-yl}phenyl acetate;

5-Methyl-7-[4-(trifluoromethyl)phenyl]-*N*-(3,4,5-trimethoxyphenyl)-imidazo[5,1-*f*][1,2,4]triazin-2-amine;

*N*-Methyl-*N'*-{4-[(5-methyl-7-phenylimidazo[5,1-*f*][1,2,4]triazin-2-yl)amino]phenyl}urea;

5-Methyl-7-phenyl-*N*-[3-(trifluoromethyl)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-amine;

(3-{5-Methyl-2-[(3,4,5-trimethoxyphenyl)amino]imidazo[5,1-*f*][1,2,4]triazin-7-yl}phenyl)(phenyl)methanone;

7-(1,3-Benzodioxol-5-yl)-5-methyl-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;

Methyl 4-{5-methyl-2-[(3,4,5-trimethoxyphenyl)amino]imidazo[5,1-*f*][1,2,4]triazin-7-yl}benzoate;

5-Methyl-7-(3-phenoxyphenyl)-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;

7-(3-Aminophenyl)-5-methyl-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;

7-(1*H*-Indol-2-yl)-5-methyl-N-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;  
5-Methyl-7-(5-nitro-1*H*-pyrrol-2-yl)-N-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;  
5-Methyl-7-(1-methyl-1*H*-pyrrol-2-yl)-N-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;  
5-Methyl-7-(1-methyl-1*H*-indol-3-yl)-N-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;  
7-(3-Furyl)-5-methyl-N-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;  
7-(1*H*-Indol-5-yl)-5-methyl-N-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;  
2-[(2-{5-Methyl-2-[(3,4,5-trimethoxyphenyl)amino]imidazo[5,1-*f*][1,2,4]triazin-7-yl}phenyl)thio]benzonitrile;  
5-Methyl-7-(2-{[3-(trifluoromethyl)phenyl]amino}phenyl)-N-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;  
5-Methyl-7-quinolin-8-yl-N-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;  
3-({5-Methyl-7-[3-(trifluoromethyl)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-yl}amino)benzenesulfonamide;  
*N*-Methyl-*N'*-[4-({5-methyl-7-[3-(trifluoromethyl)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-yl}amino)phenyl]urea;  
*N*-[4-Methoxy-3-({5-methyl-7-[3-(trifluoromethyl)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-yl}amino)phenyl]acetamide;  
2-[3-({5-Methyl-7-[3-(trifluoromethyl)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-yl}amino)phenyl]ethanol;  
4-({5-Methyl-7-[3-(trifluoromethyl)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-yl}amino)benzenesulfonamide;  
*N*-[4-({5-Methyl-7-[3-(trifluoromethyl)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-yl}amino)phenyl]acetamide;  
*N*-[3-({5-Methyl-7-[3-(trifluoromethyl)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-yl}amino)phenyl]acetamide;  
*tert*-Butyl 3-({5-methyl-7-[3-(trifluoromethyl)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-yl}amino)benzylcarbamate;  
4-({5-Methyl-7-[3-(trifluoromethyl)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-yl}amino)phenol;

5-Methyl-*N*-[4-(2-pyrrolidin-1-yethoxy)phenyl]-7-[3-(trifluoromethyl)phenyl]-imidazo[5,1-*f*][1,2,4]triazin-2-amine;  
*N*-(5-Fluoro-2-methoxyphenyl)-5-methyl-7-[3-(trifluoromethyl)phenyl]-imidazo[5,1-*f*][1,2,4]triazin-2-amine;  
*N*-{2-[4-Methoxy-3-({5-methyl-7-[3-(trifluoromethyl)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-yl}amino)phenyl]ethyl}acetamide;  
*N*-[5-(2-Aminoethyl)-2-methoxyphenyl]-5-methyl-7-[3-(trifluoromethyl)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-amine;  
*N*-(2,4-Dimethoxyphenyl)-5-methyl-7-[3-(trifluoromethyl)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-amine;  
*N*-(2,5-Dimethoxyphenyl)-5-methyl-7-[3-(trifluoromethyl)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-amine;  
Ethyl 5-({5-methyl-7-[3-(trifluoromethyl)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-yl}amino)nicotinate;  
2-{3-[(5-Methyl-7-phenylimidazo[5,1-*f*][1,2,4]triazin-2-yl)amino]phenyl}-ethanesulfonic acid;  
5-Methyl-7-[3-(1*H*-pyrazol-4-ylethynyl)phenyl]-*N*-(3,4,5-trimethoxyphenyl)-imidazo[5,1-*f*][1,2,4]triazin-2-amine;  
3'-{5-Methyl-2-[(3,4,5-trimethoxyphenyl)amino]imidazo[5,1-*f*][1,2,4]triazin-7-yl}-1,1'-biphenyl-3-carboxylic acid;  
2-Amino-3-(3'-{5-methyl-2-[(3,4,5-trimethoxyphenyl)amino]imidazo-[5,1-*f*][1,2,4]triazin-7-yl}-1,1'-biphenyl-4-yl)propanoic acid;  
5-Methyl-7-[2'-(trifluoromethyl)-1,1'-biphenyl-3-yl]-*N*-(3,4,5-trimethoxyphenyl)-imidazo[5,1-*f*][1,2,4]triazin-2-amine;  
(2Z)-3-(3-{5-Methyl-2-[(3,4,5-trimethoxyphenyl)amino]imidazo[5,1-*f*][1,2,4]triazin-7-yl}phenyl)-3-phenylprop-2-enamide;  
7-(3-{[5-(Ethylsulfonyl)-2-methoxyphenyl]amino}phenyl)-5-methyl-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;  
5-Methyl-7-(3-{[4-(1*H*-1,2,4-triazol-1-ylmethyl)phenyl]amino}phenyl)-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;  
7-(3-{[4-(1*H*-imidazol-1-yl)phenyl]amino}phenyl)-5-methyl-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;  
7-{3-[(3-Chloro-4-morpholin-4-ylphenyl)amino]phenyl}-5-methyl-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;

*N,N-Dimethyl-1-[3-[3-{5-methyl-2-[(3,4,5-trimethoxyphenyl)amino]imidazo[5,1-f][1,2,4]triazin-7-yl}phenyl]amino]phenyl}-methanesulfonamide;*  
*5-Methyl-7-[3-(4-[(4-methylpiperazin-1-yl)methyl]phenyl]-amino)phenyl]-N-(3,4,5-trimethoxyphenyl)imidazo[5,1-f][1,2,4]triazin-2-amine;*  
*N-Cyclopropyl-3-[[(3-{5-methyl-2-[(3,4,5-trimethoxyphenyl)amino]imidazo[5,1-f][1,2,4]triazin-7-yl}phenyl)amino]benzenesulfonamide;*  
*7-(5-Bromo-2-thienyl)-5-methyl-N-[4-(methyloxy)phenyl]imidazo[5,1-f][1,2,4]triazin-2-amine;*  
*7-(3-Bromo-2-thienyl)-5-methyl-N-[4-(methyloxy)phenyl]imidazo[5,1-f][1,2,4]triazin-2-amine;*  
*5-Methyl-N-[4-(methyloxy)phenyl]-7-(tetrahydro-2H-pyran-4-yl)imidazo[5,1-f][1,2,4]triazin-2-amine;*  
*5-Methyl-7-[2-(methyloxy)phenyl]-N-[4-(methyloxy)phenyl]imidazo[5,1-f][1,2,4]triazin-2-amine;*  
*5-Methyl-7-[3-(methyloxy)phenyl]-N-[4-(methyloxy)phenyl]imidazo[5,1-f][1,2,4]triazin-2-amine;*  
*7-(2-Chlorophenyl)-5-methyl-N-[4-(methyloxy)phenyl]imidazo[5,1-f][1,2,4]triazin-2-amine;*  
*5-Methyl-7-(1-methyl-1H-indol-3-yl)-N-[4-(methyloxy)phenyl]imidazo[5,1-f][1,2,4]triazin-2-amine;*  
*5-Methyl-N-[4-(methyloxy)phenyl]-7-(1-phenylethyl)imidazo[5,1-f][1,2,4]triazin-2-amine;*  
*5-Methyl-7-(1-methyl-1H-indol-2-yl)-N-[4-(methyloxy)phenyl]imidazo[5,1-f][1,2,4]triazin-2-amine;*  
*5-Methyl-N-[4-(methyloxy)phenyl]-7-(3-thienyl)imidazo[5,1-f][1,2,4]triazin-2-amine;*  
*7-(3-Furanyl)-5-methyl-N-[4-(methyloxy)phenyl]imidazo[5,1-f][1,2,4]triazin-2-amine;*  
*7-(2-Furanyl)-5-methyl-N-[4-(methyloxy)phenyl]imidazo[5,1-f][1,2,4]triazin-2-amine;*  
*7-(4-Fluorophenyl)-5-methyl-N-[4-(methyloxy)phenyl]imidazo[5,1-f][1,2,4]triazin-2-amine;*  
*5-Methyl-N-[4-(methyloxy)phenyl]-7-(2-thienyl)imidazo[5,1-f][1,2,4]triazin-2-amine;*  
*7-Cyclopropyl-5-methyl-N-[4-(methyloxy)phenyl]imidazo[5,1-f][1,2,4]triazin-2-amine;*  
*7-Cyclohexyl-5-methyl-N-[4-(methyloxy)phenyl]imidazo[5,1-f][1,2,4]triazin-2-amine;*  
*7-(2-Fluorophenyl)-5-methyl-N-[4-(methyloxy)phenyl]imidazo[5,1-f][1,2,4]triazin-2-amine;*  
*5-Methyl-N,7-bis[4-(methyloxy)phenyl]imidazo[5,1-f][1,2,4]triazin-2-amine;*

5-Methyl-N-[4-(methyloxy)phenyl]-7-(phenylmethyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;  
7-(3-Fluorophenyl)-5-methyl-N-[4-(methyloxy)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-amine;  
7-Cyclohexyl-5-methyl-N-[3,4,5-tris(methyloxy)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-amine;  
7-(Cyclohexylmethyl)-5-methyl-N-[4-(methyloxy)phenyl]-imidazo[5,1-*f*][1,2,4]triazin-2-amine;  
*N*-[3,4-Bis(methyloxy)phenyl]-5-methyl-7-phenylimidazo[5,1-*f*][1,2,4]triazin-2-amine;  
*N*-[3,5-Bis(methyloxy)phenyl]-5-methyl-7-phenylimidazo[5,1-*f*][1,2,4]triazin-2-amine;  
*N*-{4-[(5-Methyl-7-phenylimidazo[5,1-*f*][1,2,4]triazin-2-yl)amino]phenyl}acetamide;  
5-Methyl-N-[4-(methylthio)phenyl]-7-phenylimidazo[5,1-*f*][1,2,4]triazin-2-amine;  
*N*-(4-[[2-(Dimethylamino)ethyl]oxy]phenyl)-5-methyl-7-phenylimidazo[5,1-*f*][1,2,4]triazin-2-amine;  
5-Methyl-7-phenyl-*N*-(4-[[2-(1-piperidinyl)ethyl]-oxy]phenyl)-imidazo[5,1-*f*][1,2,4]triazin-2-amine;  
*N*-(3-[[2-(Dimethylamino)ethyl]oxy]phenyl)-5-methyl-7-phenylimidazo[5,1-*f*][1,2,4]triazin-2-amine;  
*N*-(1-Acetyl-2,3-dihydro-1*H*-indol-5-yl)-5-methyl-7-phenylimidazo[5,1-*f*][1,2,4]triazin-2-amine;  
*N*-Cyclohexyl-5-methyl-7-phenylimidazo[5,1-*f*][1,2,4]triazin-2-amine;  
5-Methyl-7-phenyl-*N*-(tetrahydro-2*H*-pyran-4-yl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;  
5-Methyl-*N*-(4-[[2-(4-morpholinyl)ethyl]oxy]phenyl)-7-phenylimidazo[5,1-*f*][1,2,4]triazin-2-amine;  
5-Methyl-*N*-(3-[[2-(4-morpholinyl)ethyl]oxy]phenyl)-7-phenylimidazo[5,1-*f*][1,2,4]triazin-2-amine;  
5-Methyl-*N*-[4-(methyloxy)phenyl]-7-phenylimidazo[5,1-*f*][1,2,4]triazin-2-amine;  
5-Methyl-*N*,7-diphenylimidazo[5,1-*f*][1,2,4]triazin-2-amine;  
5-Methyl-*N*-[3-(methyloxy)phenyl]-7-phenylimidazo[5,1-*f*][1,2,4]triazin-2-amine;  
and pharmaceutically acceptable salts thereof.

23. (Previously Presented) A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier, diluent or excipient.

24. (Cancelled)

25. (Previously Presented) The pharmaceutical composition according to claim 23 further comprising a chemotherapeutic agent.


26. (Cancelled)

27-28. (Cancelled)


29. (Cancelled)

30-31. (Cancelled)


32. (Previously Presented) A process for preparing a compound according to claim 1, said process comprising reacting a compound of formula (X):



33. (Previously Presented) A process for preparing a compound according to claim 1, said process comprising reacting the compound of formula (XIII):



with a compound of formula (VI):



34. (Previously Presented) A process for preparing a compound according to claim 1 wherein:

Ring A is selected from the group consisting of cycloalkyl, aryl, 5-13 membered heterocycle and 5-13 membered heteroaryl;


each R<sup>2</sup> is the same or different and is alkylene;

each R<sup>3</sup> and R<sup>4</sup> are the same or different and are each independently selected from the group consisting of H, halo, alkyl, alkenyl, alkynyl, cycloalkyl, Ph, Het, -OR<sup>5</sup>, -S(O)<sub>p</sub>R<sup>5</sup>, -S(O)<sub>2</sub>OH, -S(O)<sub>p</sub>NR<sup>5</sup>R<sup>6</sup>, -NR<sup>5</sup>R<sup>6</sup> and -NR<sup>5</sup>SO<sub>2</sub>R<sup>6</sup>;


each R<sup>5</sup> and each R<sup>6</sup> are the same or different and are each independently selected from the group consisting of H, alkyl and cycloalkyl;

Ph is phenyl optionally substituted by one or more substituents selected from the group consisting of halo, alkyl, -OR<sup>5</sup>, -SO<sub>2</sub>R<sup>5</sup>, -SO<sub>2</sub>NR<sup>5</sup>R<sup>6</sup>, -NR<sup>5</sup>R<sup>6</sup>, Het, and -R<sup>2</sup>-Het; and

Het is a monocyclic 5-6 membered heterocycle or heteroaryl group containing 1, 2 or 3 heteroatoms selected from the group consisting of N, O and S optionally substituted by one or more substituents selected from the group consisting of halo, alkyl, -OR<sup>5</sup>, -SO<sub>2</sub>R<sup>5</sup>, -SO<sub>2</sub>NR<sup>5</sup>R<sup>6</sup>, -NR<sup>5</sup>R<sup>6</sup> and oxo; and said process comprising coupling a compound of formula (XVIII):



with a compound of formula (XIX):



wherein X is Cl, Br, I or triflate.

35-46. (Cancelled)